Anti-rejection therapy is required for intestinal rejection after leukemia transplantation or other organ rejection, such as skin rejection and kidney rejection. The so-called anti-rejection therapy also refers to immunosuppressive therapy, and the drugs include glucocorticoids (methylprednisolone), cyclosporine, mertiomacrophenol ester, rucolitinib and so on. 1. Immunosuppressive anti-rejection therapy is routinely applied after leukemia transplantation. If the degree of intestinal rejection after transplantation is mild, targeted treatment, such as metoclopramide antiemetic treatment, etc., can be performed under the guidance of physicians. 2. If the degree of intestinal rejection is more serious, then it is necessary to strengthen the anti-rejection treatment, which often refers to the addition of immunosuppressive drugs, such as the addition of rucotinib, etc., or the original immune-suppressing drug dosage, but these drugs have strong side effects, such as susceptibility to infections, renal impairment, gastric ulcers, etc., and must be used in accordance with the doctor’s instructions. Intestinal rejection after leukemia transplantation can often be improved after treatment for mild cases, and the prognosis for severe cases is poorer, and can even be life-threatening. Specific drugs should be under the guidance of a physician.